ReoCure (RC402) / ViroCure - LARVOL DELTA

Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer. (PubMed, Nat Commun) - "In this preclinical study, an oncolytic reovirus (RC402) is orally administered to induce antitumor immunity...Oral reovirus treatment is most effective when combined with αPD-1(L1) and/or αCTLA-4, leading to complete colon tumor regression and protective immune memory. Collectively, oral reovirus virotherapy is a feasible and effective immunotherapeutic strategy in preclinical studies."

Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor • BATF3

A first-in-human phase 1 dose-escalation and expansion study of intratumoral oncolytic reovirus (RC402) as a monotherapy or in combination with pembrolizumab in advanced solid tumors (AACR 2024) - "This first-in-human study demonstrated IT RC402 is well tolerated and has a manageable safety profile with preliminary clinical activity as a monotherapy and in combination with pembrolizumab. These results warrant further clinical development of RC402."

Combination therapy • Metastases • Monotherapy • Oncolytic virus • P1 data • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Non-melanoma Skin Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Virocure announces phase 1 results of anti-cancer virus 'RC402' at AACR [Google translation] (Nate) - P1 | N=9 | "'Virocure'...announced its reovirus-based new drug candidate 'RC402' at the 'American Association for Cancer Research (AACR) 2024' held in San Diego, USA from the 5th to the 9th. It was announced on the 11th that the results of the phase 1 clinical trial for were announced...A phase 1 clinical trial was conducted in combination with the immune checkpoint inhibitor ‘Keytruda’ (ingredient name: pembrolizumab). As a result, it was confirmed that there was no dose-limiting toxicity, and that reovirus was not detected in samples such as saliva (saliva or sputum), blood, or feces....According to Virocure, among the 9 patients who received the combination of RC402 and Keytruda, 2 patients with skin squamous cell carcinoma achieved complete response (CR)."

P1 data • Colon Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • Squamous Cell Skin Cancer

Evaluating a combination treatment of NK cells and reovirus against bladder cancer cells using an in vitro assay to simulate intravesical therapy. (PubMed, Sci Rep) - "The anti-tumor effects of mono-treatment with reovirus type 3 Dearing strain (RC402 and RP116) and in combination with interleukin (IL)-18/-21-pretreated eNK cells were investigated on BCC lines (5637, HT-1376, and 253J-BV) using intravesical therapy to simulate in vitro model...Notably, combining RP116 with IL-18/-21-pretreated eNK cells displayed effective cytotoxicity against both HT-1376 and 253J-BV cells. Our findings underscore the potential of a combination therapy using reoviruses and NK cells as a promising strategy for treating bladder cancer."

Journal • Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • IL18

[VIRTUAL] Orally available oncolytic reovirus, RC402, effectively promotes anti-cancer immunity and synergizes with immune checkpoint blockade in colon cancer (AACR 2021) - "Our study demonstrates that orally available oncolytic reovirus, RC402, could induce potent anti-cancer immune responses and effectively suppress colon cancer progression in combination with anti-PD-1 blockade."

Checkpoint inhibition • Oncolytic virus • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD4 • CD8 • FOXP3 • IL2RA